product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
JMJD3 Antibody
catalog :
3457
clonality :
polyclonal
host :
rabbit
conjugate :
nonconjugated
reactivity :
human, mouse
application :
western blot, immunohistochemistry, immunocytochemistry
more info or order :
citations: 2
Published Application/Species/Sample/Dilution | Reference |
---|---|
| |
Sourvinos G, Morou A, Sanidas I, Codruta I, Ezell S, Doxaki C, et al. The downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 axis and by human cytomegalovirus (HCMV) associated factors allows the activation of the HCMV major IE promoter and the transition to productive infection. PLoS Pathog. 2014;10:e1004136 pubmed publisher
|
product information
SKU :
3457S
Product-Name :
JMJD3 Antibody
Size :
100 ul
Price-(USD) :
235 USD
Species-x-Reactivity :
H, M, (Mk, Hr)
Applications :
Western blot
Product-Category :
Chromatin Regulation / Nuclear Function
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Polyclonal Antibody
MW :
200
Host :
Rabbit
Target :
JMJD3
Primary-Protein :
JMJD3
Alt-Names :
JMJD3,JmjC domain-containing protein 3,Jumonji domain-containing protein 3,KDM6B,KIAA0346,Lysine demethylase 6B,Lysine-specific demethylase 6B,jumonji domain containing 3, histone lysine demethylase,lysine (K)-specific demethylase 6B
more info or order :
company information
Cell Signaling Technology
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.
review
browse more products
questions and comments